A new study validates the Scleroderma Skin Questionnaire (SSQ) as a reliable tool for assessing skin symptoms in systemic ...

Delayed esophageal transit on scintigraphy among patients with SSc is linked to a more severe disease phenotype.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by widespread vascular abnormalities, immune system activation, and skin and internal ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...

As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...

Acute and chronic renal diseases remain common complications of systemic sclerosis. Although treatment for acute scleroderma renal crisis may arrest the rapid progression of renal disease ...

Bio (NYSE:IBIO – Get Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report ...